-
2024-512448-41-00
5
2020-04-01
Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2023-509134-19-00
5
2019-10-23
Myopia
-
2023-505614-17-00
5
2019-09-20
Participants with advanced or recurrent endometrial carcinoma
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2023-508022-10-00
6
2019-07-25
Rheumatoid Arthritis
-
2023-508449-41-00
5
2019-06-26
Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
-
2022-500413-11-00
5
2019-06-17
Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
-
2024-512821-10-00
4
2019-06-17
Early invasive triple negative breast cancer with positive HRD status
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2023-503898-38-00
5
2019-05-24
Atopic Dermatitis
-
2023-509304-16-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2022-502187-20-00
5
2019-04-11
Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2023-508343-48-00
5
2019-01-25
Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
-
2022-502936-38-00
5
2019-01-09
Moderate and Severe Atopic Dermatitis
-
2024-513513-12-00
5
2019-01-06
Cholangiocarcinoma
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2024-515040-23-00
4
2018-11-26
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
-
2024-515791-12-00
3
2018-08-30
patients with external ventricular drain
-
2023-504209-35-00
5
2018-04-04
Early-Stage Resectable Non-small cell lung cancer (NSCLC)
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)